Shots: Shots: Valneva will utilize its technology and platform capabilities to develop an inactivated, whole virus vaccine candidate, VLA2001 against COVID-19 while Dynavax will provide its CpG 1018, the adjuvant used in HEPLISAV-B which is the FDA’s approved vaccine for hepatitis B Valneva is leveraging its platform that was used for IXIARO, a vaccine against […]Read More
